AMRX
Amneal Pharmaceuticals, Inc.
Price Chart
Latest Quote
$13.75
+0.23 (+1.70%)
Current Price
| Previous Close | $13.52 |
| Open | $13.58 |
| Day High | $13.88 |
| Day Low | $13.55 |
| Volume | 1,249,848 |
Stock Information
| Shares Outstanding | 319.02M |
| Total Debt | $2.70B |
| Cash Equivalents | $200.62M |
| Revenue | $3.05B |
| Net Income | $122.12M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $4.39B |
| P/E Ratio | 37.16 |
| EPS (TTM) | $0.37 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $6.97B |
| Sales | $3.05B |
| Income | $122.12M |
| Book/sh | $-0.14 |
| Cash/sh | $0.63 |
| Employees | 9K |
Financial Ratios
| Quick Ratio | 1.51 |
| Current Ratio | 2.47 |
| Debt/Eq | 6750.84 |
| EPS Growth TTM | 410.50% |
Returns & Margins
| ROA | 8.35% |
| Gross Margin | 39.17% |
| Operating Margin | 19.57% |
| Profit Margin | 4.01% |
Ownership
| Insider Ownership | 44.12% |
| Institutional Ownership | 52.15% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 12.14 |
| P/S | 1.44 |
| P/B | -96.83 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $17.20 |
Technical Indicators
| SMA20 | $12.67 |
| SMA50 | $12.75 |
| SMA200 | $12.11 |
| RSI | 79.17 |
| ATR | 0.3980 |
| Shares Float | 178.41M |
| Short Float | 3.84% |
| Short Ratio | 4.90 |
| Volatility | 1.32 |
| Rel Volume | 0.82 |
Performance History
| Week | +4.40% |
| Month | +0.95% |
| Quarter | +3.85% |
| 6 Months | +12.89% |
| YTD | +8.61% |
| Year | +90.71% |
| 3 Years | +487.61% |
| 5 Years | +142.93% |
| 10 Years | -8.39% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $13.75 | 1,295,000 |
| 2026-06-04 | $13.52 | 1,743,100 |
| 2026-06-03 | $12.88 | 1,204,500 |
| 2026-06-02 | $12.65 | 2,074,000 |
| 2026-06-01 | $12.90 | 1,401,300 |
| 2026-05-29 | $13.17 | 2,188,000 |
| 2026-05-28 | $12.95 | 2,031,900 |
| 2026-05-27 | $12.78 | 1,525,400 |
| 2026-05-26 | $12.79 | 2,125,200 |
| 2026-05-22 | $12.42 | 953,500 |
| 2026-05-21 | $12.42 | 1,653,500 |
| 2026-05-20 | $12.23 | 1,624,100 |
| 2026-05-19 | $11.81 | 1,387,100 |
| 2026-05-18 | $11.92 | 1,316,000 |
| 2026-05-15 | $11.93 | 1,332,000 |
| 2026-05-14 | $12.23 | 1,879,900 |
| 2026-05-13 | $12.39 | 1,458,300 |
| 2026-05-12 | $12.60 | 1,266,400 |
| 2026-05-11 | $12.78 | 1,637,600 |
| 2026-05-08 | $13.20 | 1,519,900 |
| 2026-05-07 | $13.72 | 2,009,700 |
| 2026-05-06 | $13.62 | 1,302,700 |
About Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
đ° Latest News
How The Amneal Pharmaceuticals (AMRX) Story Is Shifting With Biosimilars And 2026 Expectations
Simply Wall St. âĸ 2026-06-06T05:05:59Z
Amneal Stock Up on FDA Nod for Romidepsin Injection Solution
Zacks âĸ 2026-06-05T15:30:00Z
Why Amneal (AMRX) Stock Is Trading Up Today
StockStory âĸ 2026-06-05T03:33:30Z
3 Profitable Stocks with Open Questions
StockStory âĸ 2026-06-04T17:25:30Z
Is Amneal Pharmaceuticals (AMRX) Stock Undervalued Right Now?
Zacks âĸ 2026-06-01T13:40:04Z
Q4 Earnings Highlights: Amneal (NASDAQ:AMRX) Vs The Rest Of The Generic Pharmaceuticals Stocks
StockStory âĸ 2026-05-27T17:53:24Z
Is it a Good Idea to Invest in Amneal Pharmaceuticals Stock Now?
Zacks âĸ 2026-05-26T16:11:00Z
3 Reasons Why Growth Investors Shouldn't Overlook Amneal (AMRX)
Zacks âĸ 2026-05-15T16:45:02Z
Should Value Investors Buy Amneal Pharmaceuticals (AMRX) Stock?
Zacks âĸ 2026-05-15T13:40:03Z
2 Reasons AMRX is Risky and 1 Stock to Buy Instead
StockStory âĸ 2026-05-14T20:12:55Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $1,905,452,000 | $1,773,519,000 | $1,573,042,000 | $1,427,596,000 |
| Cost Of Revenue | $1,905,452,000 | $1,773,519,000 | $1,573,042,000 | $1,427,596,000 |
| Total Revenue | $3,018,760,000 | $2,793,957,000 | $2,393,607,000 | $2,212,304,000 |
| Operating Revenue | $3,018,760,000 | $2,793,957,000 | $2,393,607,000 | $2,212,304,000 |
| Expenses | ||||
| Interest Expense | $241,091,000 | $258,595,000 | $210,629,000 | $158,377,000 |
| Total Expenses | $2,620,846,000 | $2,445,584,000 | $2,154,860,000 | $2,023,382,000 |
| Other Income Expense | $13,751,000 | $-144,791,000 | $-27,583,000 | $-278,381,000 |
| Other Non Operating Income Expenses | $16,522,000 | $11,782,000 | $8,243,000 | $18,464,000 |
| Net Non Operating Interest Income Expense | $-272,456,000 | $-258,595,000 | $-251,434,000 | $-158,668,000 |
| Total Other Finance Cost | $31,365,000 | - | $40,805,000 | $291,000 |
| Interest Expense Non Operating | $241,091,000 | $258,595,000 | $210,629,000 | $158,377,000 |
| Operating Expense | $715,394,000 | $672,065,000 | $581,818,000 | $595,786,000 |
| Other Operating Expenses | $-5,240,000 | $-930,000 | $-15,635,000 | $-3,960,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $72,057,000 | $-116,886,000 | $-83,993,000 | $-129,986,000 |
| Net Interest Income | $-272,456,000 | $-258,595,000 | $-251,434,000 | $-158,668,000 |
| Normalized Income | $74,603,549 | $6,806,670 | $-55,690,460 | $104,521,550 |
| Net Income From Continuing And Discontinued Operation | $72,057,000 | $-116,886,000 | $-83,993,000 | $-129,986,000 |
| Total Operating Income As Reported | $394,096,000 | $249,326,000 | $204,374,000 | $-94,928,000 |
| Net Income Common Stockholders | $72,057,000 | $-116,886,000 | $-83,993,000 | $-129,986,000 |
| Net Income | $72,057,000 | $-116,886,000 | $-83,993,000 | $-129,986,000 |
| Net Income Including Noncontrolling Interests | $127,933,000 | $-73,876,000 | $-48,722,000 | $-254,789,000 |
| Net Income Continuous Operations | $127,933,000 | $-73,876,000 | $-48,722,000 | $-254,789,000 |
| Pretax Income | $139,209,000 | $-55,013,000 | $-40,270,000 | $-248,127,000 |
| Special Income Charges | $-10,406,000 | $-149,727,000 | $-37,497,000 | $-284,481,000 |
| Operating Income | $397,914,000 | $348,373,000 | $238,747,000 | $188,922,000 |
| Gross Profit | $1,113,308,000 | $1,020,438,000 | $820,565,000 | $784,708,000 |
| Per Share | ||||
| Diluted EPS | $0.22 | $-0.38 | $-0.48 | $-0.86 |
| Basic EPS | $0.23 | $-0.38 | $-0.48 | $-0.86 |
| Other | ||||
| Tax Effect Of Unusual Items | $-224,451 | $-32,880,330 | $-7,523,460 | $-62,337,450 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $606,643,000 | $596,346,000 | $435,585,000 | $447,270,000 |
| Total Unusual Items | $-2,771,000 | $-156,573,000 | $-35,826,000 | $-296,845,000 |
| Total Unusual Items Excluding Goodwill | $-2,771,000 | $-156,573,000 | $-35,826,000 | $-296,845,000 |
| Reconciled Depreciation | $223,572,000 | $236,191,000 | $229,400,000 | $240,175,000 |
| EBITDA (Bullshit earnings) | $603,872,000 | $439,773,000 | $399,759,000 | $150,425,000 |
| EBIT | $380,300,000 | $203,582,000 | $170,359,000 | $-89,750,000 |
| Diluted Average Shares | $324,805,000 | $308,978,000 | $176,136,000 | $150,944,000 |
| Basic Average Shares | $313,367,000 | $308,978,000 | $176,136,000 | $150,944,000 |
| Diluted NI Availto Com Stockholders | $72,057,000 | $-116,886,000 | $-83,993,000 | $-129,986,000 |
| Minority Interests | $-55,876,000 | $-43,010,000 | $-35,271,000 | $124,803,000 |
| Tax Provision | $11,276,000 | $18,863,000 | $8,452,000 | $6,662,000 |
| Other Special Charges | $6,198,000 | $147,372,000 | $35,748,000 | $281,620,000 |
| Restructuring And Mergern Acquisition | $4,208,000 | $2,355,000 | $1,749,000 | $2,861,000 |
| Gain On Sale Of Security | $7,635,000 | $-6,846,000 | $1,671,000 | $-12,364,000 |
| Research And Development | $193,807,000 | $196,559,000 | $167,778,000 | $200,046,000 |
| Selling General And Administration | $526,827,000 | $476,436,000 | $429,675,000 | $399,700,000 |
| Other Taxes | - | $50,680,000 | $3,124,000 | $631,000 |
| Gain On Sale Of Business | - | - | - | $0 |
Fetched: 2026-06-06
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-1,229,762,000 | $-1,439,080,000 | $-1,469,271,000 | $-1,396,525,000 |
| Total Assets | $3,678,280,000 | $3,501,445,000 | $3,472,569,000 | $3,799,341,000 |
| Total Non Current Assets | $1,767,099,000 | $1,913,639,000 | $2,094,706,000 | $2,387,523,000 |
| Other Non Current Assets | $9,305,000 | $5,278,000 | $7,126,000 | $8,191,000 |
| Non Current Prepaid Assets | $37,547,000 | $16,114,000 | $6,875,000 | $7,234,000 |
| Non Current Deferred Assets | $5,197,000 | $2,820,000 | $4,427,000 | $2,206,000 |
| Financial Assets | $5,756,000 | $35,921,000 | $37,089,000 | $85,586,000 |
| Goodwill And Other Intangible Assets | $1,158,968,000 | $1,329,813,000 | $1,489,052,000 | $1,694,946,000 |
| Other Intangible Assets | $563,498,000 | $732,377,000 | $890,423,000 | $1,096,093,000 |
| Current Assets | $1,911,181,000 | $1,587,806,000 | $1,377,863,000 | $1,411,818,000 |
| Restricted Cash | $28,842,000 | $7,868,000 | $7,565,000 | $9,251,000 |
| Prepaid Assets | $54,134,000 | $48,368,000 | $51,712,000 | $48,946,000 |
| Inventory | $606,302,000 | $612,454,000 | $581,384,000 | $530,735,000 |
| Receivables | $939,874,000 | $808,564,000 | $645,660,000 | $796,910,000 |
| Other Receivables | $25,599,000 | $15,520,000 | $17,805,000 | $41,738,000 |
| Taxes Receivable | $18,662,000 | $16,829,000 | $13,168,000 | $12,881,000 |
| Accounts Receivable | $895,143,000 | $775,731,000 | $613,732,000 | $741,791,000 |
| Allowance For Doubtful Accounts Receivable | $-845,181,000 | $-528,057,000 | $-586,248,000 | $-603,168,000 |
| Gross Accounts Receivable | $1,740,324,000 | $1,303,788,000 | $1,199,980,000 | $1,344,959,000 |
| Cash Cash Equivalents And Short Term Investments | $282,029,000 | $110,552,000 | $91,542,000 | $25,976,000 |
| Cash And Cash Equivalents | $282,029,000 | $110,552,000 | $91,542,000 | $25,976,000 |
| Debt | ||||
| Net Debt | $2,289,847,000 | $2,375,451,000 | $2,549,034,000 | $2,695,672,000 |
| Total Debt | $2,689,046,000 | $2,593,139,000 | $2,750,523,000 | $2,845,135,000 |
| Long Term Debt And Capital Lease Obligation | $2,667,470,000 | $2,252,884,000 | $2,522,899,000 | $2,740,496,000 |
| Long Term Debt | $2,565,115,000 | $2,161,790,000 | $2,427,451,000 | $2,631,687,000 |
| Current Debt And Capital Lease Obligation | $21,576,000 | $340,255,000 | $227,624,000 | $104,639,000 |
| Current Debt | $6,761,000 | $324,213,000 | $213,125,000 | $89,961,000 |
| Other Current Borrowings | $6,761,000 | $224,213,000 | $34,125,000 | $29,961,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $3,749,609,000 | $3,610,957,000 | $3,452,558,000 | $3,615,362,000 |
| Total Non Current Liabilities Net Minority Interest | $2,867,976,000 | $2,481,186,000 | $2,605,963,000 | $2,862,562,000 |
| Other Non Current Liabilities | $92,728,000 | $94,051,000 | $8,215,000 | $70,168,000 |
| Tradeand Other Payables Non Current | $0 | $1,252,000 | $497,000 | $563,000 |
| Current Liabilities | $881,633,000 | $1,129,771,000 | $846,595,000 | $752,800,000 |
| Other Current Liabilities | $43,256,000 | $31,755,000 | $76,988,000 | $107,483,000 |
| Payables And Accrued Expenses | $736,915,000 | $684,802,000 | $470,861,000 | $486,640,000 |
| Interest Payable | $18,663,000 | $1,585,000 | - | - |
| Payables | $310,156,000 | $281,002,000 | $161,119,000 | $178,685,000 |
| Accounts Payable | $254,671,000 | $258,691,000 | $143,572,000 | $165,980,000 |
| Other Payable | - | $10,226,000 | $10,226,000 | $10,226,000 |
| Derivative Product Liabilities | - | - | - | $0 |
| Total Tax Payable | - | - | - | $359,000 |
| Equity | ||||
| Common Stock Equity | $-70,794,000 | $-109,267,000 | $19,781,000 | $298,421,000 |
| Total Equity Gross Minority Interest | $-71,329,000 | $-109,512,000 | $20,011,000 | $183,979,000 |
| Stockholders Equity | $-70,794,000 | $-109,267,000 | $19,781,000 | $298,421,000 |
| Gains Losses Not Affecting Retained Earnings | $-110,729,000 | $-65,510,000 | $-32,349,000 | $9,939,000 |
| Other Equity Adjustments | $-110,729,000 | $-65,510,000 | $-32,349,000 | $9,939,000 |
| Retained Earnings | $-535,005,000 | $-607,062,000 | $-490,176,000 | $-406,183,000 |
| Preferred Securities Outside Stock Equity | $77,292,000 | $64,974,000 | $41,293,000 | $24,949,000 |
| Other | ||||
| Ordinary Shares Number | $314,565,000 | $309,881,000 | $306,565,000 | $151,490,000 |
| Share Issued | $314,565,000 | $309,881,000 | $306,565,000 | $151,490,000 |
| Tangible Book Value | $-1,229,762,000 | $-1,439,080,000 | $-1,469,271,000 | $-1,396,525,000 |
| Invested Capital | $2,501,082,000 | $2,376,736,000 | $2,660,357,000 | $3,020,069,000 |
| Working Capital | $1,029,548,000 | $458,035,000 | $531,268,000 | $659,018,000 |
| Capital Lease Obligations | $117,170,000 | $107,136,000 | $109,947,000 | $123,487,000 |
| Total Capitalization | $2,494,321,000 | $2,052,523,000 | $2,447,232,000 | $2,930,108,000 |
| Minority Interest | $-535,000 | $-245,000 | $230,000 | $-114,442,000 |
| Additional Paid In Capital | $571,794,000 | $560,206,000 | $539,240,000 | $691,629,000 |
| Capital Stock | $3,146,000 | $3,099,000 | $3,066,000 | $3,036,000 |
| Common Stock | $3,146,000 | $3,099,000 | $3,066,000 | $3,036,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Employee Benefits | $11,354,000 | $17,125,000 | $21,283,000 | $16,737,000 |
| Dueto Related Parties Non Current | $19,132,000 | $50,900,000 | $11,776,000 | $9,649,000 |
| Long Term Capital Lease Obligation | $102,355,000 | $91,094,000 | $95,448,000 | $108,809,000 |
| Current Capital Lease Obligation | $14,815,000 | $16,042,000 | $14,499,000 | $14,678,000 |
| Line Of Credit | $0 | $100,000,000 | $179,000,000 | $60,000,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $79,886,000 | $72,959,000 | $71,122,000 | $54,038,000 |
| Current Accrued Expenses | $426,759,000 | $403,800,000 | $309,742,000 | $307,955,000 |
| Dueto Related Parties Current | $55,485,000 | $22,311,000 | $7,321,000 | $2,479,000 |
| Goodwill | $595,470,000 | $597,436,000 | $598,629,000 | $598,853,000 |
| Net PPE | $550,326,000 | $523,693,000 | $550,137,000 | $589,360,000 |
| Accumulated Depreciation | $-606,170,000 | $-563,520,000 | $-508,027,000 | $-445,971,000 |
| Gross PPE | $1,156,496,000 | $1,087,213,000 | $1,058,164,000 | $1,035,331,000 |
| Leases | $133,833,000 | $130,905,000 | $126,461,000 | $124,668,000 |
| Construction In Progress | $92,909,000 | $78,198,000 | $67,665,000 | $69,344,000 |
| Other Properties | $107,376,000 | $98,785,000 | $102,563,000 | $119,545,000 |
| Machinery Furniture Equipment | $568,089,000 | $546,558,000 | $524,614,000 | $485,438,000 |
| Buildings And Improvements | $234,599,000 | $224,655,000 | $227,837,000 | $225,630,000 |
| Land And Improvements | $19,690,000 | $8,112,000 | $9,024,000 | $10,706,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $323,494,000 | $351,922,000 | $304,077,000 | $247,606,000 |
| Work In Process | $55,455,000 | $52,835,000 | $59,563,000 | $58,522,000 |
| Raw Materials | $227,353,000 | $207,697,000 | $217,744,000 | $224,607,000 |
| Duefrom Related Parties Current | $470,000 | $484,000 | $955,000 | $500,000 |
Fetched: 2026-06-06
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $225,635,000 | $220,109,000 | $276,388,000 | $-25,495,000 |
| Operating Activities | ||||
| Operating Cash Flow | $339,992,000 | $295,099,000 | $345,577,000 | $65,100,000 |
| Cash Flow From Continuing Operating Activities | $339,992,000 | $295,099,000 | $345,577,000 | $65,100,000 |
| Operating Gains Losses | $-7,453,000 | $7,191,000 | $-768,000 | $15,190,000 |
| Investing Activities | ||||
| Capital Expenditure | $-114,357,000 | $-74,990,000 | $-69,189,000 | $-90,595,000 |
| Investing Cash Flow | $-112,263,000 | $-62,996,000 | $-69,189,000 | $-174,309,000 |
| Cash Flow From Continuing Investing Activities | $-112,263,000 | $-62,996,000 | $-69,189,000 | $-174,309,000 |
| Net Other Investing Changes | - | - | - | $1,000,000 |
| Financing Activities | ||||
| Financing Cash Flow | $-31,530,000 | $-211,791,000 | $-212,573,000 | $-106,620,000 |
| Cash Flow From Continuing Financing Activities | $-31,530,000 | $-211,791,000 | $-212,573,000 | $-106,620,000 |
| Net Other Financing Charges | $-134,732,000 | $-27,827,000 | $-235,676,000 | $-69,010,000 |
| Other | ||||
| Repayment Of Debt | $-2,811,508,000 | $-233,118,000 | $-414,080,000 | $-123,272,000 |
| Issuance Of Debt | $2,912,750,000 | $48,000,000 | $436,732,000 | $85,000,000 |
| Interest Paid Supplemental Data | $197,848,000 | $263,518,000 | $192,806,000 | $142,722,000 |
| Income Tax Paid Supplemental Data | $21,327,000 | $15,220,000 | $2,496,000 | $12,649,000 |
| End Cash Position | $312,939,000 | $118,420,000 | $99,107,000 | $35,227,000 |
| Beginning Cash Position | $118,420,000 | $99,107,000 | $35,227,000 | $256,739,000 |
| Effect Of Exchange Rate Changes | $-1,680,000 | $-999,000 | $65,000 | $-5,683,000 |
| Changes In Cash | $196,199,000 | $20,312,000 | $63,815,000 | $-215,829,000 |
| Proceeds From Stock Option Exercised | $1,960,000 | $1,154,000 | $451,000 | $662,000 |
| Net Issuance Payments Of Debt | $101,242,000 | $-185,118,000 | $22,652,000 | $-38,272,000 |
| Net Short Term Debt Issuance | $-2,593,508,000 | $-140,918,000 | $-195,080,000 | $85,000,000 |
| Short Term Debt Payments | $-2,811,508,000 | $-188,918,000 | $-414,080,000 | - |
| Short Term Debt Issuance | $218,000,000 | $48,000,000 | $219,000,000 | $85,000,000 |
| Net Long Term Debt Issuance | $2,694,750,000 | $-44,200,000 | $217,732,000 | $-123,272,000 |
| Long Term Debt Payments | $0 | $-44,200,000 | $0 | $-123,272,000 |
| Long Term Debt Issuance | $2,694,750,000 | $0 | $217,732,000 | $0 |
| Net Business Purchase And Sale | $0 | $11,994,000 | $0 | $-84,714,000 |
| Sale Of Business | $0 | $11,994,000 | $0 | $0 |
| Net Intangibles Purchase And Sale | $-15,514,000 | $-14,650,000 | $-22,388,000 | $-41,800,000 |
| Purchase Of Intangibles | $-15,514,000 | $-14,650,000 | $-22,388,000 | $-41,800,000 |
| Net PPE Purchase And Sale | $-96,749,000 | $-60,340,000 | $-46,801,000 | $-48,795,000 |
| Sale Of PPE | $2,094,000 | $0 | $0 | - |
| Purchase Of PPE | $-98,843,000 | $-60,340,000 | $-46,801,000 | $-48,795,000 |
| Change In Working Capital | $-204,516,000 | $-4,068,000 | $-47,186,000 | $-59,945,000 |
| Change In Payables And Accrued Expense | $22,252,000 | $289,576,000 | $-84,617,000 | $111,640,000 |
| Change In Payable | $22,252,000 | $289,576,000 | $-84,617,000 | $111,640,000 |
| Change In Account Payable | $21,321,000 | $235,135,000 | $-94,446,000 | $109,568,000 |
| Change In Prepaid Assets | $-19,163,000 | $-959,000 | $37,814,000 | $9,882,000 |
| Change In Inventory | $-87,026,000 | $-130,530,000 | $-126,182,000 | $-102,396,000 |
| Change In Receivables | $-120,579,000 | $-162,155,000 | $125,799,000 | $-79,071,000 |
| Changes In Account Receivables | $-120,566,000 | $-162,637,000 | $126,289,000 | $-79,717,000 |
| Other Non Cash Items | $59,757,000 | $4,415,000 | $44,413,000 | $17,445,000 |
| Stock Based Compensation | $31,953,000 | $27,768,000 | $26,822,000 | $31,847,000 |
| Provisionand Write Offof Assets | $85,962,000 | $96,558,000 | $74,686,000 | $51,096,000 |
| Asset Impairment Charge | $22,784,000 | $920,000 | $66,932,000 | $24,081,000 |
| Depreciation Amortization Depletion | $223,572,000 | $236,191,000 | $229,400,000 | $240,175,000 |
| Depreciation And Amortization | $223,572,000 | $236,191,000 | $229,400,000 | $240,175,000 |
| Net Foreign Currency Exchange Gain Loss | $-7,453,000 | $7,191,000 | $-768,000 | $15,190,000 |
| Net Income From Continuing Operations | $127,933,000 | $-73,876,000 | $-48,722,000 | $-254,789,000 |
| Purchase Of Business | - | $0 | $0 | $-84,714,000 |
| Amortization Cash Flow | - | - | $163,200,000 | $172,063,000 |
| Amortization Of Intangibles | - | - | $163,200,000 | $172,063,000 |
| Depreciation | - | - | $66,200,000 | $68,112,000 |
| Gain Loss On Sale Of Business | - | - | - | $0 |
| Deferred Tax | - | - | - | - |
| Deferred Income Tax | - | - | - | - |
| Gain Loss On Sale Of PPE | - | - | - | - |
Fetched: 2026-06-06